Literature DB >> 8822109

Epidermal growth factor receptor immunoreactivity in gallbladder and extrahepatic biliary tract tumours.

C S Lee1, A Pirdas.   

Abstract

Elevated levels of epidermal growth factor receptor (EGFR), a transmembrane protein tyrosine kinase receptor, are found in carcinomas from various sites of the body. We investigated the expression of EGFR in carcinoma of the gallbladder (n = 13), common bile duct (n = 7) and ampulla of Vater (n = 9). Non-malignant conditions investigated include chronic cholecystitis (n = 11), gallbladder dysplasia (n = 3) and adenoma (n = 1), and ampullary carcinoma in situ (CIS) (n = 2). Routine immunohistochemistry was employed using a monoclonal antibody against the EGFR protein. Immunostaining was assessed according to both intensity and extent of staining of cells. There was strong immunoreactivity for all gallbladder carcinoma and adenoma, the majority of common bile duct (n = 6; 86%) and ampullary (n = 6; 67%) carcinoma. In contrast, all cases of gallbladder dysplasia, the majority of cases of chronic cholecystitis (n = 7; 64%) and ampullary CIS (n = 2; 67%) had only weak to moderate immunoreactivity. The pattern of immunoreactivity was one of diffuse cytoplasmic and membranous staining. In conclusion, EGFR expression is increased in both gallbladder, common bile duct and ampullary carcinomas but not in non-malignant conditions of the gallbladder and biliary tract. These findings suggest that EGFR overexpression occurs late in the sequential development of gallbladder and biliary tract cancers.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8822109     DOI: 10.1016/S0344-0338(11)80652-7

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  17 in total

1.  MUC5AC, a gel-forming mucin accumulating in gallstone disease, is overproduced via an epidermal growth factor receptor pathway in the human gallbladder.

Authors:  Laetitia Finzi; Véronique Barbu; Pierre-Regis Burgel; Martine Mergey; Kimberly S Kirkwood; Elizabeth C Wick; Jean-Yves Scoazec; Frédérique Peschaud; François Paye; Jay A Nadel; Chantal Housset
Journal:  Am J Pathol       Date:  2006-12       Impact factor: 4.307

2.  Evaluation of phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) and epidermal growth factor receptor (EGFR) gene mutations in pancreaticobiliary adenocarcinoma.

Authors:  Guy A Weiss; Michael R Rossi; Nikhil I Khushalani; Ken Lo; John F Gibbs; Anubha Bharthuar; John K Cowell; Renuka Iyer
Journal:  J Gastrointest Oncol       Date:  2013-03

3.  Co-expression of cox-2, C-met and beta-catenin in cells forming invasive front of gallbladder cancer.

Authors:  Woo Sung Moon; Ho Sung Park; Ho Lee; Rama Pai; Andrzej S Tarnawski; Kyung Ryoul Kim; Kyu Yun Jang
Journal:  Cancer Res Treat       Date:  2005-06-30       Impact factor: 4.679

4.  HER Receptor Family: Novel Candidate for Targeted Therapy for Gallbladder and Extrahepatic Bile Duct Cancer.

Authors:  Toru Kawamoto; Savitri Krishnamurthy; Emily Tarco; Smita Trivedi; Ignacio I Wistuba; Donghui Li; Ivan Roa; Juan C Roa; Melanie B Thomas
Journal:  Gastrointest Cancer Res       Date:  2007-11

Review 5.  c-Met targeted therapy of cholangiocarcinoma.

Authors:  Matei-P Socoteanu; Frank Mott; Gianfranco Alpini; Arthur-E Frankel
Journal:  World J Gastroenterol       Date:  2008-05-21       Impact factor: 5.742

6.  Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers.

Authors:  Elizabeth R Kessler; S Gail Eckhardt; Todd M Pitts; Erica L Bradshaw-Pierce; Cindy L O'byrant; Wells A Messersmith; Sujatha Nallapreddy; Colin Weekes; Jennifer Spratlin; Christopher H Lieu; Madeleine A Kane; Sarah Eppers; Elizabeth Freas; Stephen Leong
Journal:  Invest New Drugs       Date:  2015-12-30       Impact factor: 3.850

7.  Role of EGFR and HER-2/NEU Expression in Gall Bladder Carcinoma (GBC).

Authors:  Chhanda Das; Madhumita Mukhopadhyay; Srijana Subba; Ashis Kumar Saha; Biswanath Mukhopadhyay
Journal:  J Lab Physicians       Date:  2021-05-19

Review 8.  Chemotherapy for the biliary tract cancers: moving toward improved survival time.

Authors:  Adriana Romiti; Chiara D'Antonio; Angelo Zullo; Ida Sarcina; Roberta Di Rocco; Viola Barucca; Valeria Durante; Paolo Marchetti
Journal:  J Gastrointest Cancer       Date:  2012-09

9.  Expression of phospho-ERK1/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations.

Authors:  Qinglong Li; Zhulin Yang
Journal:  J Exp Clin Cancer Res       Date:  2009-05-18

Review 10.  A genetic model for gallbladder carcinogenesis and its dissemination.

Authors:  S G Barreto; A Dutt; A Chaudhary
Journal:  Ann Oncol       Date:  2014-04-04       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.